John Segreti to Staphylococcus aureus
This is a "connection" page, showing publications John Segreti has written about Staphylococcus aureus.
Connection Strength
0.841
-
Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit Care Clin. 2008 Apr; 24(2):249-60, vii-viii.
Score: 0.313
-
Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago. Antimicrob Agents Chemother. 2018 08; 62(8).
Score: 0.160
-
Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2015 Sep; 59(9):5232-8.
Score: 0.129
-
Empirical therapy for serious Gram-positive infections: making the right choice. Clin Microbiol Infect. 2009 Dec; 15 Suppl 6:5-10.
Score: 0.088
-
In vitro activity of minocycline and rifampin against staphylococci. Diagn Microbiol Infect Dis. 1989 May-Jun; 12(3):253-5.
Score: 0.084
-
Hot topics in necrotising skin and soft tissue infections. Int J Antimicrob Agents. 2018 Jul; 52(1):1-10.
Score: 0.039
-
A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother. 2013 Dec; 68(12):2921-6.
Score: 0.028